Floatz logo

SUMOYLATION INHIBITOR TAK-981

Lymphoma, Non-Hodgkin

TakedaSmall moleculePhase 1/2Dormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
13/ 100
Competitive Position
73/ 100

Competitive context

411 Active assets in the Lymphoma, Non-Hodgkin cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

SUMOYLATION INHIBITOR TAK-981 is also rated in:

Advanced or Metastatic Solid TumorsDormant
D
Indicative ·
30 / 100
View asset →
neoplasmDormant
D
Indicative ·
29 / 100
View asset →
plasma cell myelomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →